. Author manuscript; available in PMC: 2009 Jan 8.

Published in final edited form as: Cancer Prev Res (Phila). 2008 Oct;1(5):357–361. doi: 10.1158/1940-6207.CAPR-08-0061

Table 2.

Frequency of gene methylation^* in EBC samples, according to each patient’s worst endoscopic biopsy diagnosis.

		Worst Biopsy Diagnosis (# patients)^†
Gene	Normal	Esophagitis	Mild Dysplasia	Moderate Dysplasia	Severe Dysplasia
Gene	n=50	n=25	n=25	n=26	n=21
AHRR	3 (6%)	3 (12%)	1 (4%)	4 (15%)	4 (20%)
p16	5 (10%)	2 (8%)	1 (4%)	3 (12%)	3 (14%)
CRBP	6 (12%)	4 (16%)	3 (12%)	4 (15%)	2 (10%)
CLDN3	6 (12%)	9 (28%)	8 (32%)	9 (35%)	7 (34%)
MT1G	2 (4%)	1 (4%)	3 (12%)	1 (4%)	3 (14%)
MGMT	3 (6%)	2 (8%)	2 (8%)	1 (4%)	3 (14%)
PGP9.5	0 (0%)	1 (4%)	0 (0%)	1 (4%)	3 (14%)
RARb2	0 (0%)	1 (4%)	0 (0%)	2 (8%)	2 (10%)

Gene methylation evaluated as a dichotomous variable (any/none) (see methods).

^†

Non parametric test for trend across the worst endoscopic biopsy diagnosis categories: AHRR ptrend=0.101, p16 p=0.641, CRBP p=0.915, CLDN3 p=0.029, MT1G p=0.188, MGMT p=0.484, PGP9.5 p=0.014, RARb2 p=0.031.